Royalty Reports and Payments. After the first sale of a Product on which royalties are payable by a Party hereunder, such Party shall make quarterly written reports to the other Party within sixty (60) days after the end of each calendar quarter, stating in each such report, separately the number, description, and aggregate Net Sales, by territory, of each such Product sold during the calendar quarter upon which a royalty is payable under Section 6.3 or Section 6.4 above, as applicable. Concurrently with the making of such reports, such Party shall pay to the other Party royalties due at the rates specified in Section 6.3 or Section 6.4 above, as applicable.
Royalty Reports and Payments. After the first commercial sale of Products on which royalties are required, Licensee agrees to make quarterly written reports to XT within eighty days after the end of each calendar quarter, stating in each such report the number, description, and aggregate Net Sales of Products sold during the calendar quarter upon which a royalty is payable under Article 4 above. Concurrently with the making of such reports, Licensee shall pay to XT royalties at the applicable rate specified in Section 4.1, 4.2 or 4.4 above and all royalties payable pursuant to Section 5.1 above, and any adjustment to Net Sales for a prior period in accordance with the definition of Net Sales in Section 1.11 hereof. All payments to XT hereunder shall be made in U.S. Dollars to a bank account designated by XT.
Royalty Reports and Payments. After the first sale of any Licensed Product, Licensee shall deliver written reports to CareFusion for each calendar quarter within forty-five (45) days after the end of such quarter, stating in each such report, separately for Licensee, its Affiliates and applicable Sublicensees, the number and description of each Licensed Product, by country, the gross revenues in respect thereof, the calculations and itemizations of all permitted deductions to arrive at Net Sales, and the calculation of Royalties due thereon. Concurrent with the delivery of the report required pursuant to this Section 5.1, Licensee shall pay to CareFusion all Royalties that have accrued hereunder as of the close of the prior calendar quarter that is covered by such report.
Royalty Reports and Payments. Within [***] days following the end of each calendar quarter following the First Commercial Sale of a Product upon which Product Royalties are payable anywhere in the Territory, Artiva shall provide GCLC with a report containing the following information for the applicable calendar quarter, on a Product-by-Product and country-by-country basis: (i) Net Sales of such Product in such country; (ii) the basis for any adjustments to royalties due to GCLC on account of Net Sales of such Product in such country; (iii) a calculation of the royalty payment due to GCLC on account of Net Sales of such Product in such country; and (iv) the exchange rate used in calculating any of the foregoing; provided that the obligations under this Section 3.2(c) may be satisfied by the report due by Artiva to GCLC under Section 6.1(c) of the Option Agreement. Concurrent with the delivery of the applicable quarterly report, Artiva shall pay the royalty payment due to GCLC pursuant to this Section 3.2 for such calendar quarter.
Royalty Reports and Payments. Within [***] ([***]) [***] following the end of the 2nd, 3rd and 4th calendar quarters of each calendar year, commencing with the calendar quarter in which the First Commercial Sale of any Product is made anywhere in the Territory, Takeda shall provide ITI with a reasonably detailed report containing the following information for the applicable calendar quarter, on a country-by-country and Product-by-Product basis: (i) the gross sales of such Product in the Territory, (ii) a reasonable calculation of the tentative amount of Net Sales in the Territory showing total amount of deductions, to the extent practicable, provided for in the definition of “Net Sales”, subject to a final adjustment to be made by Takeda at the end of Takeda’s fiscal year (April 1 to March 31), (iii) a calculation of the royalty payment due on such sales, (iv) the exchange rate for such country, and (v) the application of the reduction and adjustment, if any, made in accordance with the terms of Section 8.5(c). Concurrent with the delivery of the applicable quarterly report, Takeda shall pay in Dollars all amounts due to ITI pursuant to Section 8.5 with respect to Net Sales by Takeda, its Affiliates and their respective sublicensees for such calendar quarter. Within sixty (60) days following the end of each March, Takeda shall provide ITI with a report containing the following information for the preceding one (1) year (from April 1 to March 31), on a country-by-country and Product-by-Product basis: (i) gross sales of such Product in the Territory, (ii) a reasonable calculation of Net Sales in the Territory showing total amount of deductions for such fiscal year, including the 1st calendar quarter, to the extent practicable, provided for in the definition of “Net Sales”, (iii) a calculation of the royalty payment due on such sales, (iv) the exchange rate for such country, (v) the application of the reduction and adjustment, if any, made in accordance with the terms of Section 8.5(c), and (vi) a calculation of the necessary adjustment for the difference between amount of royalty calculated based on tentative Net Sales and those based on the Net Sales finally adjusted. Concurrent with the delivery of such annual report, Takeda shall pay in Dollars all amounts due to ITI pursuant to Section 8.5 with respect to Net Sales for the 1st calendar quarter, as adjusted to reflect Takeda’s calculation of Net Sales for Takeda’s most recently completed fiscal year. Notwithstanding the foregoing, in ...
Royalty Reports and Payments. Within [...***...] following the end of each calendar quarter following the First Commercial Sale of a Licensed Product anywhere in the Territory, Lumena shall provide Sanofi with a report containing the following information for the applicable calendar quarter, on a Licensed Product-by-Licensed Product and country-by-country basis: (i) the amount of gross sales of such Licensed Product in such country, (ii) an itemized calculation of Net Sales in such country showing deductions provided for in the definition of Net Sales in Section 1.31, (iii) a calculation of the royalty payment due on such sales, (iv) an accounting of the number of units and prices for Licensed Product sold, (v) the exchange rate for such country (as published in The Wall Street Journal, Eastern Edition, on the last business day of the last month in the calendar quarter to which such payments relate), and (vi) the date of First Commercial Sale of such Licensed Product in such country. Concurrent with the delivery of the applicable quarterly report, Lumena shall pay all amounts due to Sanofi pursuant to this Section 3.5 with respect to Net Sales by Lumena, its Affiliates and their respective sublicensees and subcontractors for such calendar quarter.
Royalty Reports and Payments. Within sixty (60) days following the end of each calendar quarter, commencing with the calendar quarter in which the First Commercial Sale of any Product is made anywhere in the world, GSK shall provide Liquidia with a report setting forth the Net Sales of each Product on a country-by-country basis and the royalties due on such Products. Concurrent with the delivery of the applicable quarterly report, GSK shall pay in Dollars all amounts due to Liquidia pursuant to Section 10.5 with respect to Net Sales by GSK, its Affiliates and their respective sublicensees for such calendar quarter.
Royalty Reports and Payments. Royalty reports and payments shall be due sixty (60) days after the close of each Reporting Period. Payment of royalties in whole or in part may be made in advance of such due date. In case no royalty is due for any given Reporting Period, Licensee shall so report to Licensor. Licensee and its Sublicensees shall keep accurate records in sufficient detail to enable the royalty payable hereunder to be determined and confirmed. Licensee shall be responsible for all royalties, late payments, and interest that are due but have not been paid by Licensee's Sublicensees.
Royalty Reports and Payments. After the first commercial sale by Fuso or its Affiliates or Sublicensees of a Collaboration Product for which royalties are payable under Article 3, Fuso shall make quarterly written reports to GenVec within thirty (30) days after the end of each calendar quarter, stating in each such report, by country, the number, description and aggregate Net Sales of such Collaboration Product sold during the calendar quarter. Simultaneously with the delivery of each such report, Fuso shall pay to GenVec the total royalties, if any, due to GenVec for the period of such report. If no royalties are due, Fuso shall so report.
Royalty Reports and Payments. 7.1 After the first commercial sale of a PRODUCT or AURORA'S UC REAGENTS on which royalties are required hereunder, PACKARD shall make quarterly written reports to AURORA within thirty (30) days after the end of each calendar quarter, stating in each such report the aggregate Net Sales of the PRODUCTS and AURORA UC REAGENTS sold during the calendar quarter upon which a royalty is payable hereunder, and an annual report on or before February 28 of each year stating the number, description and aggregate Net Sales of PRODUCTS and AURORA UC REAGENTS sold during the preceding calendar year. AURORA shall treat all such reports as confidential information of PACKARD. Concurrently with the making of such reports, PACKARD shall pay to AURORA the applicable royalties specified in this Agreement.
7.2 Royalties due hereunder shall be paid in U.S. dollars. All checks and bank drafts shall be drawn on United States banks and shall be payable to AURORA at the address listed herein.
7.3 If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the selling exchange rate for conversion of the foreign currency into U.S. dollars, quoted for current transactions reported in The Wall Street Journal for the last business day of the calendar quarter to which such payment pertains.
7.4 PACKARD shall keep complete, true, and accurate books of account and records, including number and description of PRODUCTS and AURORA UC REAGENTS sold, for the purpose of determining the royalty amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of PACKARD for at least three (3) years following the end of the calendar quarter to which such books and records pertain. Such books and records shall be open for inspection at the principal place of business of PACKARD during such three (3) year period by a representative selected by AURORA for the purpose of verifying the royalty statements. Such inspections shall be made at reasonable times as mutually agreed. The representative will be obliged to execute a reasonable confidentiality agreement on terms consistent with the terms of this Agreement prior to commencing any such inspection. Inspections conducted under this Article shall be at the expense of AURORA, unless a variation or error producing *** of the amount stated as having been due by PACKARD for any period covered by the inspection is established in the co...
